S9511: A southwest oncology group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach

Charles Blanke, Kari Chansky, Kathy L. Christman, Scott A. Hundahl, Brian F. Issell, Peter J. Van Veldhuizen, G. Thomas Budd, James L. Abbruzzese, John S. MacDonald

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: The primary objective of this trial was to evaluate the response rate for trimetrexate in conjunction with 5-FU and leucovorin (LV) (= TFL) in the treatment of advanced gastric cancer in a phase II, cooperative group setting. Methods: Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours × 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression. Results: Characteristics for 37 eligible patients: median age 63 (range: 23-83); male/female: 69% of 31%; performance status 0/1/2 15/20/1. The confirmed response rate was 19%, and median overall survival was 6 months. Two patients died as a result of therapy, 1 because of infection without significant neutropenia, and 1 due to perforation of a responding gastric lesion. Seventy-two percent experienced grades 3 and 4 toxicity, most commonly diarrhea, fatigue, and lymphopenia. Conclusions: This regimen achieves response rates comparable to other 5-FU-based regimens, when used in treatment of incurable gastric cancer. Toxicity appears manageable.

Original languageEnglish (US)
Pages (from-to)117-120
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume33
Issue number2
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Trimetrexate
Leucovorin
Fluorouracil
Stomach
Adenocarcinoma
Stomach Neoplasms
Lymphopenia
Neutropenia
Fatigue
Diarrhea
Therapeutics
Survival
Infection

Keywords

  • Chemotherapy
  • Gastric neoplasms
  • Trimetrexate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

S9511 : A southwest oncology group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. / Blanke, Charles; Chansky, Kari; Christman, Kathy L.; Hundahl, Scott A.; Issell, Brian F.; Van Veldhuizen, Peter J.; Budd, G. Thomas; Abbruzzese, James L.; MacDonald, John S.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 33, No. 2, 04.2010, p. 117-120.

Research output: Contribution to journalArticle

Blanke, Charles ; Chansky, Kari ; Christman, Kathy L. ; Hundahl, Scott A. ; Issell, Brian F. ; Van Veldhuizen, Peter J. ; Budd, G. Thomas ; Abbruzzese, James L. ; MacDonald, John S. / S9511 : A southwest oncology group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2010 ; Vol. 33, No. 2. pp. 117-120.
@article{3196e7024c4a426fa011464830433a71,
title = "S9511: A southwest oncology group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach",
abstract = "Objective: The primary objective of this trial was to evaluate the response rate for trimetrexate in conjunction with 5-FU and leucovorin (LV) (= TFL) in the treatment of advanced gastric cancer in a phase II, cooperative group setting. Methods: Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours × 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression. Results: Characteristics for 37 eligible patients: median age 63 (range: 23-83); male/female: 69{\%} of 31{\%}; performance status 0/1/2 15/20/1. The confirmed response rate was 19{\%}, and median overall survival was 6 months. Two patients died as a result of therapy, 1 because of infection without significant neutropenia, and 1 due to perforation of a responding gastric lesion. Seventy-two percent experienced grades 3 and 4 toxicity, most commonly diarrhea, fatigue, and lymphopenia. Conclusions: This regimen achieves response rates comparable to other 5-FU-based regimens, when used in treatment of incurable gastric cancer. Toxicity appears manageable.",
keywords = "Chemotherapy, Gastric neoplasms, Trimetrexate",
author = "Charles Blanke and Kari Chansky and Christman, {Kathy L.} and Hundahl, {Scott A.} and Issell, {Brian F.} and {Van Veldhuizen}, {Peter J.} and Budd, {G. Thomas} and Abbruzzese, {James L.} and MacDonald, {John S.}",
year = "2010",
month = "4",
doi = "10.1097/COC.0b013e318199fb84",
language = "English (US)",
volume = "33",
pages = "117--120",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - S9511

T2 - A southwest oncology group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach

AU - Blanke, Charles

AU - Chansky, Kari

AU - Christman, Kathy L.

AU - Hundahl, Scott A.

AU - Issell, Brian F.

AU - Van Veldhuizen, Peter J.

AU - Budd, G. Thomas

AU - Abbruzzese, James L.

AU - MacDonald, John S.

PY - 2010/4

Y1 - 2010/4

N2 - Objective: The primary objective of this trial was to evaluate the response rate for trimetrexate in conjunction with 5-FU and leucovorin (LV) (= TFL) in the treatment of advanced gastric cancer in a phase II, cooperative group setting. Methods: Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours × 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression. Results: Characteristics for 37 eligible patients: median age 63 (range: 23-83); male/female: 69% of 31%; performance status 0/1/2 15/20/1. The confirmed response rate was 19%, and median overall survival was 6 months. Two patients died as a result of therapy, 1 because of infection without significant neutropenia, and 1 due to perforation of a responding gastric lesion. Seventy-two percent experienced grades 3 and 4 toxicity, most commonly diarrhea, fatigue, and lymphopenia. Conclusions: This regimen achieves response rates comparable to other 5-FU-based regimens, when used in treatment of incurable gastric cancer. Toxicity appears manageable.

AB - Objective: The primary objective of this trial was to evaluate the response rate for trimetrexate in conjunction with 5-FU and leucovorin (LV) (= TFL) in the treatment of advanced gastric cancer in a phase II, cooperative group setting. Methods: Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours × 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression. Results: Characteristics for 37 eligible patients: median age 63 (range: 23-83); male/female: 69% of 31%; performance status 0/1/2 15/20/1. The confirmed response rate was 19%, and median overall survival was 6 months. Two patients died as a result of therapy, 1 because of infection without significant neutropenia, and 1 due to perforation of a responding gastric lesion. Seventy-two percent experienced grades 3 and 4 toxicity, most commonly diarrhea, fatigue, and lymphopenia. Conclusions: This regimen achieves response rates comparable to other 5-FU-based regimens, when used in treatment of incurable gastric cancer. Toxicity appears manageable.

KW - Chemotherapy

KW - Gastric neoplasms

KW - Trimetrexate

UR - http://www.scopus.com/inward/record.url?scp=77951049357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951049357&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e318199fb84

DO - 10.1097/COC.0b013e318199fb84

M3 - Article

C2 - 19770625

AN - SCOPUS:77951049357

VL - 33

SP - 117

EP - 120

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -